Minor emtricitabine intolerance in treatment-stable patients switched from tenofovir/lamivudine to a fixed-dose combination of tenofovir/ emtricitabine (Truvada®) [8]

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 2, 2008, Pages 462-463

  Palacios, Rosario ^a   Terrón, Alberto ^b   Hidalgo, Ana ^a   Rivero, Antonio ^c   Santos, Jesús ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b HOSPITAL DE JEREZ   (Spain)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Adverse reactions; Antiretroviral therapy; Treatment

Indexed keywords

EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; TENOFOVIR;

CENTRAL NERVOUS SYSTEM DISEASE; CONFUSION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPIGMENTATION; INSOMNIA; IRRITABILITY; LETTER; MAJOR CLINICAL STUDY; MYALGIA; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; SIDE EFFECT; SPAIN; SWEATING; UNSPECIFIED SIDE EFFECT;

ADENINE; DEOXYCYTIDINE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; HUMANS; LAMIVUDINE; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 38349172948     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm489     Document Type: Letter

References (4)

1. Bang LM, Scott LJ. Emtricitabine: An antiretroviral agent for HIV infection. Drugs 2003; 63: 2413-24; discussion 2425-6.
2. Benson CA, van der Horst C, Lamarca A et al. A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV. AIDS 2004; 18: 2669-76.
3. Pollock K, Stebbing J, Bower M et al. Emtricitabine intolerance in treatment-experienced patients switched from lamivudine: A method of assessing toxicity. J Antimicrob Chemother 2006; 58: 227-8.
4. Villar del Saz S, Milinkovic A, Domingo P et al. Tolerability of emtricitabine (FTC) in HIV infected subjects who switch from lamivudine (3TC) to FTC. In: Abstracts of the Fourth IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia, 2007. Abstract MOPEB012.